DLD Asset Management’s Terns Pharmaceuticals TERN Stock Holding History

DLD Asset Management’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.48M	Buy	47,025 +42,025	+841%	+$1.73M	0.23%	58
2025 Q4	$202K	Sell	5,000 -5,000	-50%	-$116K	0.01%	281
2025 Q3	$75.1K	Sell	10,000 -27,047	-73%	-$173K	0.01%	279
2025 Q2	$138K	Buy	+37,047	New	+$116K	0.01%	218

Other funds holding TERN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

DLD Asset Management's TERN Position: Q1 2026 in Review

DLD Asset Management increased its Terns Pharmaceuticals (TERN) stake by 841% in Q1 2026, buying an estimated $1.73M and bringing the position to 47,025 shares worth $2.48M. The position accounts for 0.23% of the portfolio, ranked #58.

DLD Asset Management first reported a position in TERN in Q2 2025 and has held it in 4 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

DLD Asset Management held 47,025 shares of Terns Pharmaceuticals worth $2.48M as of Q1 2026.
DLD Asset Management bought 42,025 Terns Pharmaceuticals shares in Q1 2026, an estimated $1.73M.
Terns Pharmaceuticals made up 0.23% of DLD Asset Management's portfolio in Q1 2026, its #58 holding.
DLD Asset Management first reported a position in Terns Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on DLD Asset Management's 13F filing for Q1 2026, filed 13 May 2026.